641 related articles for article (PubMed ID: 28342971)
1. A novel dual GLP-1/GIP receptor agonist alleviates cognitive decline by re-sensitizing insulin signaling in the Alzheimer icv. STZ rat model.
Shi L; Zhang Z; Li L; Hölscher C
Behav Brain Res; 2017 Jun; 327():65-74. PubMed ID: 28342971
[TBL] [Abstract][Full Text] [Related]
2. The novel GLP-1/GIP analogue DA5-CH reduces tau phosphorylation and normalizes theta rhythm in the icv. STZ rat model of AD.
Li C; Liu W; Li X; Zhang Z; Qi H; Liu S; Yan N; Xing Y; Hölscher C; Wang Z
Brain Behav; 2020 Mar; 10(3):e01505. PubMed ID: 31960630
[TBL] [Abstract][Full Text] [Related]
3. Neuroprotective effects of a triple GLP-1/GIP/glucagon receptor agonist in the APP/PS1 transgenic mouse model of Alzheimer's disease.
Tai J; Liu W; Li Y; Li L; Hölscher C
Brain Res; 2018 Jan; 1678():64-74. PubMed ID: 29050859
[TBL] [Abstract][Full Text] [Related]
4. DA5-CH, a novel GLP-1/GIP dual agonist, effectively ameliorates the cognitive impairments and pathology in the APP/PS1 mouse model of Alzheimer's disease.
Cao Y; Hölscher C; Hu MM; Wang T; Zhao F; Bai Y; Zhang J; Wu MN; Qi JS
Eur J Pharmacol; 2018 May; 827():215-226. PubMed ID: 29551659
[TBL] [Abstract][Full Text] [Related]
5. A novel dual-glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptor agonist is neuroprotective in transient focal cerebral ischemia in the rat.
Han L; Hölscher C; Xue GF; Li G; Li D
Neuroreport; 2016 Jan; 27(1):23-32. PubMed ID: 26555034
[TBL] [Abstract][Full Text] [Related]
6. A novel GLP-1/GIP dual receptor agonist protects from 6-OHDA lesion in a rat model of Parkinson's disease.
Jalewa J; Sharma MK; Gengler S; Hölscher C
Neuropharmacology; 2017 May; 117():238-248. PubMed ID: 28223210
[TBL] [Abstract][Full Text] [Related]
7. A novel dual GLP-1 and GIP receptor agonist is neuroprotective in the MPTP mouse model of Parkinson's disease by increasing expression of BNDF.
Ji C; Xue GF; Lijun C; Feng P; Li D; Li L; Li G; Hölscher C
Brain Res; 2016 Mar; 1634():1-11. PubMed ID: 26453833
[TBL] [Abstract][Full Text] [Related]
8. Neuroprotective and restorative properties of the GLP-1/GIP dual agonist DA-JC1 compared with a GLP-1 single agonist in Alzheimer's disease.
Salles GN; Calió ML; Hölscher C; Pacheco-Soares C; Porcionatto M; Lobo AO
Neuropharmacology; 2020 Jan; 162():107813. PubMed ID: 31628935
[TBL] [Abstract][Full Text] [Related]
9. [GLP-1/GIP/Gcg receptor Triagonist improves the cognitive behaviors in triple-transgenic mice of Alzheimer's disease].
Jiao JJ; Hölscher C; Li T; Dong XF; Qu XS; Cao Y; Wu MN; Wang ZJ; Qi JS
Sheng Li Xue Bao; 2017 Apr; 69(2):135-145. PubMed ID: 28435972
[TBL] [Abstract][Full Text] [Related]
10. Two novel dual GLP-1/GIP receptor agonists are neuroprotective in the MPTP mouse model of Parkinson's disease.
Feng P; Zhang X; Li D; Ji C; Yuan Z; Wang R; Xue G; Li G; Hölscher C
Neuropharmacology; 2018 May; 133():385-394. PubMed ID: 29462693
[TBL] [Abstract][Full Text] [Related]
11. Neuroprotection of GLP-1/GIP receptor agonist via inhibition of mitochondrial stress by AKT/JNK pathway in a Parkinson's disease model.
Li T; Tu L; Gu R; Yang XL; Liu XJ; Zhang GP; Wang Q; Ren YP; Wang BJ; Tian JY
Life Sci; 2020 Sep; 256():117824. PubMed ID: 32445758
[TBL] [Abstract][Full Text] [Related]
12. A novel GLP-1/GIP/Gcg triagonist reduces cognitive deficits and pathology in the 3xTg mouse model of Alzheimer's disease.
Li T; Jiao JJ; Hölscher C; Wu MN; Zhang J; Tong JQ; Dong XF; Qu XS; Cao Y; Cai HY; Su Q; Qi JS
Hippocampus; 2018 May; 28(5):358-372. PubMed ID: 29473979
[TBL] [Abstract][Full Text] [Related]
13. Pseudoginsenoside-F11 attenuates cognitive dysfunction and tau phosphorylation in sporadic Alzheimer's disease rat model.
Zhu L; Hou XJ; Che XH; Zhou TS; Liu XQ; Wu CF; Yang JY
Acta Pharmacol Sin; 2021 Sep; 42(9):1401-1408. PubMed ID: 33277592
[TBL] [Abstract][Full Text] [Related]
14. Grape Seed Proanthocyanidin Extract Ameliorates Streptozotocin-induced Cognitive and Synaptic Plasticity Deficits by Inhibiting Oxidative Stress and Preserving AKT and ERK Activities.
Gao WL; Li XH; Dun XP; Jing XK; Yang K; Li YK
Curr Med Sci; 2020 Jun; 40(3):434-443. PubMed ID: 32681248
[TBL] [Abstract][Full Text] [Related]
15. The Novel DA-CH3 Dual Incretin Restores Endoplasmic Reticulum Stress and Autophagy Impairments to Attenuate Alzheimer-Like Pathology and Cognitive Decrements in the APPSWE/PS1ΔE9 Mouse Model.
Panagaki T; Gengler S; Hölscher C
J Alzheimers Dis; 2018; 66(1):195-218. PubMed ID: 30282365
[TBL] [Abstract][Full Text] [Related]
16. Dulaglutide ameliorates STZ induced AD-like impairment of learning and memory ability by modulating hyperphosphorylation of tau and NFs through GSK3β.
Zhou M; Chen S; Peng P; Gu Z; Yu J; Zhao G; Deng Y
Biochem Biophys Res Commun; 2019 Mar; 511(1):154-160. PubMed ID: 30773255
[TBL] [Abstract][Full Text] [Related]
17. Chromium picolinate attenuates cognitive deficit in ICV-STZ rat paradigm of sporadic Alzheimer's-like dementia via targeting neuroinflammatory and IRS-1/PI3K/AKT/GSK-3β pathway.
Akhtar A; Dhaliwal J; Saroj P; Uniyal A; Bishnoi M; Sah SP
Inflammopharmacology; 2020 Apr; 28(2):385-400. PubMed ID: 31898080
[TBL] [Abstract][Full Text] [Related]
18. Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer's and Parkinson's disease models.
Hölscher C
Neuropharmacology; 2018 Jul; 136(Pt B):251-259. PubMed ID: 29402504
[TBL] [Abstract][Full Text] [Related]
19. The Novel Dual GLP-1/GIP Receptor Agonist DA-CH5 Is Superior to Single GLP-1 Receptor Agonists in the MPTP Model of Parkinson's Disease.
Zhang L; Zhang L; Li Y; Li L; Melchiorsen JU; Rosenkilde M; Hölscher C
J Parkinsons Dis; 2020; 10(2):523-542. PubMed ID: 31958096
[TBL] [Abstract][Full Text] [Related]
20. Long-term treatment with intranasal insulin ameliorates cognitive impairment, tau hyperphosphorylation, and microglial activation in a streptozotocin-induced Alzheimer's rat model.
Guo Z; Chen Y; Mao YF; Zheng T; Jiang Y; Yan Y; Yin X; Zhang B
Sci Rep; 2017 Apr; 7():45971. PubMed ID: 28382978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
